CDBIO(SH:688739)2023-04-27 16:00Financial Performance - Total operating revenue for Q1 2023 was ¥353,522,532.16, a decrease of 3.3% compared to ¥366,344,805.12 in Q1 2022[10] - Net profit for Q1 2023 was ¥127,042,894.67, down 15.8% from ¥150,924,190.74 in Q1 2022[13] - Basic earnings per share for Q1 2023 was ¥0.31, compared to ¥0.36 in Q1 2022[13] - The net profit attributable to shareholders was ¥127,042,894.67, down 15.82% year-over-year[67] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥116,031,504.20, a decrease of 12.66%[67] Cash Flow and Liquidity - Cash and cash equivalents decreased to ¥4,457,113,803.32 as of March 31, 2023, from ¥5,796,844,904.91 at the end of 2022, a decline of 23.2%[1] - Operating cash flow for Q1 2023 was CNY 108,573,617.95, a significant increase from CNY 38,146,275.72 in Q1 2022, representing a growth of 184.9%[17] - Cash flow from operating activities in Q1 2023 was ¥116,045,231.68, significantly up from ¥56,620,176.53 in Q1 2022[31] - The total cash outflow from investing activities was ¥80,689,094.44 in Q1 2023, down from ¥171,949,891.74 in Q1 2022, indicating a decrease of 53.0%[31] - The total cash and cash equivalents at the end of the period amounted to 4,419,334,512.81 RMB, down from 5,734,512,816.08 RMB at the beginning of the period, reflecting a net decrease of 1,315,178,303.27 RMB[32] Assets and Liabilities - Total liabilities decreased to ¥329,025,993.68 from ¥406,164,634.49, a decline of 19.0%[7] - Total assets increased to CNY 10,161,858,720.69 as of March 31, 2023, up from CNY 10,068,803,034.83 at the end of 2022, marking a growth of 0.9%[20] - The company’s total liabilities decreased to CNY 1,200,000,000.00 in Q1 2023 from CNY 1,300,000,000.00 in Q1 2022, indicating a reduction of 7.7%[20] - The total equity increased to ¥9,966,413,609.80 in Q1 2023 from ¥9,814,372,200.91 in Q1 2022, an increase of 1.5%[22] - The total assets at the end of the reporting period were ¥10,105,714,849.31, reflecting a slight increase of 0.50% from the previous year[69] Expenses and Financial Costs - Total operating costs increased to ¥212,419,296.10 in Q1 2023, up 5.4% from ¥201,559,233.50 in Q1 2022[10] - The company reported a financial expense of -¥18,769,658.90 in Q1 2023, compared to -¥7,738,013.69 in Q1 2022, indicating an increase in financial costs[10] - Research and development expenses increased to ¥38,203,065.95 in Q1 2023, compared to ¥29,011,936.92 in Q1 2022, reflecting a growth of 31.8%[28] - The financial expenses showed a notable change, with a net financial income of -¥19,904,436.80 in Q1 2023 compared to -¥8,481,778.36 in Q1 2022[28] Shareholder Information - Shareholders' equity increased to ¥9,776,688,855.63 from ¥9,649,585,884.87, an increase of 1.3%[7] - The diluted earnings per share for the period was ¥0.31, a decrease of 13.89% year-over-year[69] - The total number of common shareholders at the end of the reporting period was 31,729[73] Investment Activities - Total cash inflow from investment activities in Q1 2023 was CNY 152,547,164.84, down from CNY 900,502,577.04 in Q1 2022, indicating a decrease of 83.0%[18] - Net cash outflow from investment activities was CNY -1,446,928,942.17 in Q1 2023, compared to CNY -540,349,528.56 in Q1 2022, reflecting a worsening of 167.5%[18] - The company’s cash outflow from financing activities was CNY 906,051.56 in Q1 2023, compared to CNY 570,729.18 in Q1 2022, representing an increase of 58.7%[18]